Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (E/C/F/TDF, Stribild) is recommended for adults and adolescents with HIV -- but only for those with estimated creatinine clearance (CrCl) greater than 70 mL per minute.
The medication is a once-daily tablet, which should be taken with food. Each tablet contains: 150 mg of elvitegravir (Vitekta), 150 mg of cobicistat (Tybost), 200 mg of emtricitabine (FTC, Emtriva) and 300 mg of tenofovir disoproxil fumarate (Viread, TDF).
Elvitegravir is part of the integrase inhibitor class, known for its potency and safety, while cobicistat is a booster drug that raises levels of elvitegravir in the blood. Together with emtricitabine and TDF, two nucleoside analog reverse transcriptase inhibitors (or "nukes"), the regimen is recommended as a first-line option for those starting treatment.
TDF, the older version of tenofovir, may cause kidney damage, so it's important to monitor patient creatinine levels.
See full prescribing information here for additional warnings and indications.